Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes

医学 内科学 2型糖尿病 心肌梗塞 糖尿病 回顾性队列研究 心房颤动 冲程(发动机) 病历 人口 2型糖尿病 二肽基肽酶-4抑制剂 心力衰竭 疾病 内分泌学 工程类 环境卫生 机械工程
作者
Hsuan-Yu Su,Chen‐Yi Yang,Yu‐Hsuan Lee,Pei‐Fang Su,Yi-Chia Liu,Huang‐Tz Ou
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (10): e2441765-e2441765
标识
DOI:10.1001/jamanetworkopen.2024.41765
摘要

Importance Cardiovascular disease (CVD) can be recurrent during type 2 diabetes (T2D) progression in this aging population. The effectiveness of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy on total (ie, first and subsequent) CVD among patients with T2D in clinical practice remains uncertain. Objective To analyze the comparative association of SGLT2i vs dipeptidyl peptidase 4 inhibitor (DPP4i) therapy with total CVD among patients with T2D in clinical practice. Design, Setting, and Participants This retrospective cohort study used electronic medical records at the National Cheng Kung University Hospital, a leading medical center in Taiwan, from 2015 through 2021. Adult patients with T2D who initiated first use of the study drugs from 2016 through 2019, with up to 6 years of follow-up, were identified. Main Outcomes and Measures The primary outcomes included total composite CVD events and individual CVD subtypes (ie, atrial fibrillation, coronary heart disease, heart failure, stroke, myocardial infarction, and transient ischemic attack). A shared frailty model analysis was used to assess the association of treatment with repeat CVD events. Data from patients at high risk for CVD recurrence were further analyzed. Data were analyzed from September 1, 2022, to December 31, 2023. Results Overall, 8384 patients with T2D were identified (mean [SD] age, 63.7 [12.4] years; 4645 [55.4%] male). A total of 1632 propensity score–matched pairs of SGLT2i (mean [SD] age, 57.8 [12.0] years; 673 [41.2%] female and 959 [58.8%] male) and DPP4i (mean [SD] age, 58.2 [12.9] years; 655 [40.1%] female and 977 [59.9%] male) users were included. SGLT2i was associated with reduced total CVD risk vs DPP4i therapy (hazard ratio [HR], 0.82 [95% CI, 0.69-0.98]) but not the first CVD event (with the use of SGLT2i therapy were more prominent for patients at high risk of CVD (ie, HR, 0.70 [95% CI, 0.62-0.80] for individuals with estimated glomerular filtration rate lower than 60 mL/min/1.73 m 2 ; HR, 0.70 [95% CI, 0.64-0.78]; for individuals having any diabetes-related complications; and HR, 0.72 [95% CI, 0.65-0.80] for individuals with a history of CVD) compared with the overall cohort. Among patients at high risk of CVD, greater reduced total CVD burden associated with SGLT2i therapy was observed for women vs men (eg, HR, 0.59 [95% CI, 0.49-0.72] in the subgroup with CVD history). Conclusions and Relevance In this cohort study of patients with T2D, the use of SGLT2is vs DPP4is was associated with reduced total cardiovascular burden, suggesting that long-term use of this therapy may optimize treatment benefit among patients with chronic CVD. The SGLT2i-associated benefit among patients with high risk of CVD encourages the prioritization of SGLT2i use for these vulnerable individuals.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助科研通管家采纳,获得10
刚刚
一石二鸟应助科研通管家采纳,获得10
刚刚
qing_he应助科研通管家采纳,获得10
1秒前
Tung完成签到,获得积分10
1秒前
星辰大海应助科研通管家采纳,获得10
1秒前
薰硝壤应助科研通管家采纳,获得10
1秒前
斯文败类应助zxr采纳,获得10
1秒前
充电宝应助科研通管家采纳,获得10
1秒前
大个应助科研通管家采纳,获得10
1秒前
薰硝壤应助科研通管家采纳,获得10
1秒前
JamesPei应助科研通管家采纳,获得10
1秒前
顾矜应助科研通管家采纳,获得30
1秒前
栗子发布了新的文献求助10
1秒前
慕青应助科研通管家采纳,获得10
2秒前
NexusExplorer应助科研通管家采纳,获得30
2秒前
Maestro_S应助科研通管家采纳,获得20
2秒前
NexusExplorer应助科研通管家采纳,获得10
2秒前
小马甲应助科研通管家采纳,获得10
2秒前
2秒前
斯文败类应助科研通管家采纳,获得10
2秒前
小马甲应助科研通管家采纳,获得10
2秒前
2秒前
李爱国应助科研通管家采纳,获得10
2秒前
云汐儿应助科研通管家采纳,获得10
2秒前
Micahaeler发布了新的文献求助10
4秒前
4秒前
顾北发布了新的文献求助10
5秒前
早睡早起发布了新的文献求助10
5秒前
bju发布了新的文献求助10
5秒前
Kylin完成签到,获得积分10
6秒前
甲乙丙丁发布了新的文献求助10
6秒前
6秒前
风中的宛白应助Siney采纳,获得10
6秒前
香蕉觅云应助材料小刘鸭采纳,获得10
7秒前
Kimberley关注了科研通微信公众号
7秒前
薰硝壤应助KEYANMINGONG采纳,获得10
8秒前
正能量完成签到 ,获得积分10
8秒前
歪哔巴布完成签到,获得积分10
9秒前
自由飞扬完成签到 ,获得积分10
9秒前
10秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135943
求助须知:如何正确求助?哪些是违规求助? 2786734
关于积分的说明 7779353
捐赠科研通 2442999
什么是DOI,文献DOI怎么找? 1298768
科研通“疑难数据库(出版商)”最低求助积分说明 625232
版权声明 600870